Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

TeleStroke-Guided Thrombolysis for Acute Ischemic Stroke in Oman

19 de julho de 2026 atualizado por: Oman Ministry of Health

Thrombolysis for Acute Ischemic Stroke Facilitated by TeleStroke: Oman TeleStroke Initiative

The goal of this study is to establish and examine the efficacy of using a Telestroke network in Oman to facilitate using emergent thrombolysis for patients with acute ischemic stroke encountered in selected peripheral hospitals. It is proposed to establish a TeleStroke network involving two central hospitals in Muscat linked to three to five peripheral hospitals in Oman which currently have access to CT scans and basic infrastructure for management of AIS patients- but do not have a Neurology service. Selected staff from Internal Medicine/Emergency Medicine departments, Nursing, Technical service and support staffs will be trained in the process of assessment and management of AIS patients including the use of IV alteplase or tenecteplase. They will also be trained in timely access of a Neurologist on call at the central hospital(s) using a TeleStroke network. The Neurologist would conduct a Telestroke based clinical assessment of the AIS patient, review imaging and laboratory results in a timely manner and advice the medical team at the peripheral hospital regarding administration of IV alteplase/tenecteplase. The main purpose of such consultation would be to recognize eligible patients for administration of IV thrombolysis safely at the earliest opportunity within 4.5 hours, leading to increased rates of such thrombolysis with expected improved outcomes. Outcomes would be compared among 100 patients with AIS managed across these 5 hospitals prior to initiation of the practice of thrombolysis and at least 100 patients treated each with IV alteplase using TeleStroke Consultation with Neurologist. Demonstration of efficacy of TeleStroke based stroke thrombolysis would lead to effective implementation of this practice in Oman.

Visão geral do estudo

Status

Ainda não está recrutando

Intervenção / Tratamento

Descrição detalhada

Stroke is the second leading cause of death globally and the primary cause of long-term disability. Timely management of acute ischemic stroke (AIS) requires emergent administration of intravenous thrombolytics (alteplase or tenecteplase) within 4.5 hours of symptom onset, often followed by triage for possible thrombectomy. However, many peripheral hospitals, particularly in regions like Oman, lack the specialized neurological expertise necessary for this time-sensitive management.

Telemedicine, specifically 'TeleStroke,' has emerged as a crucial solution in numerous countries and communities to bridge this gap, enabling remote neurological support for acute stroke thrombolysis. The Oman TeleStroke Initiative aims to establish and evaluate the efficacy of such a network.

Study Objectives:

This study aims to:

Establish a TeleStroke 'hub' center within one or two major hospitals in Muscat with existing neurologic services.

Develop 'spoke' TeleStroke centers in five peripheral hospitals (Rustaq, Ibra, Buraimi, Ibri, and Sur) by identifying and engaging multidisciplinary participating teams (Internal Medicine, Emergency Medicine, Imaging, Laboratory, Nursing, Technical support).

Train senior physician-led teams at spoke hospitals in TeleStroke-based acute stroke management protocols, specifically focusing on intravenous thrombolysis.

Educate broader medical and paramedical teams in overall acute stroke management and decision-making processes.

Sequentially initiate acute stroke thrombolysis services at peripheral centers following a stepped-wedge trial model.

Conduct 3-5 mock TeleStroke-based stroke thrombolysis cycles at each peripheral center to ensure readiness and troubleshoot protocols.

Support and monitor 20 stroke care encounters for thrombolysis at each spoke center.

Document demographic data, stroke type and severity (NIH Stroke Scale, GCS), main neurologic deficits, risk factors, discharge outcome (neurologic deficits; NISS; modified Rankin Score), and 3-month outcome for two patient groups at each center: 30 patients receiving conventional management before TeleStroke initiation and 20 patients after TeleStroke-facilitated thrombolysis.

Conduct a comprehensive cost-benefit analysis.

Compare outcomes and cost-benefit between cohorts before and after TeleStroke initiation.

Facilitate handover of the project to a standing committee managed by participating hospitals upon project completion.

Study Design and Setting:

This is an implementation study utilizing a stepped-wedge randomized trial model. The project will establish a TeleStroke network comprising one or two expert 'hub' hospitals in Muscat linked to five 'spoke' hospitals in the periphery (Rustaq, Ibra, Buraimi, Ibri, and Sur). The sequential initiation of thrombolysis services at spoke centers under TeleStroke guidance will allow for observation of conventional management (control phase) followed by the intervention phase at each site.

Intervention and Training:

The intervention involves the implementation of a TeleStroke network and comprehensive training. At peripheral hospitals, 2-3 dedicated senior physicians from Internal Medicine and Emergency Medicine will be trained in acute stroke management, focusing on thrombolytic care. This training will include didactic lectures, case discussions, hands-on sessions (e.g., NIH Stroke Scale administration), CT evaluation in acute stroke, thrombolysis decision-making, post-thrombolysis care, and communication skills. Related medical and paramedical teams (Nursing, Physical Medicine) will also receive training in overall acute stroke and post-stroke patient management. Essential IT infrastructure (computers with audio-video, image/lab upload capabilities) will be provided, and a dedicated computer application for systematic communication and documentation will be adapted. Mock encounters will be practiced at each center to refine protocols and achieve short door-to-needle times.

Key Management Steps:

Eligible patients will undergo a rapid assessment including focused history ("last known to be normal" time), neurological exam (NIHSS, GCS), vital signs, and urgent investigations (blood glucose, CBC, U&E, ECG, CT brain plain, with CTA if available). If eligible for IV alteplase, consent will be obtained, and a TeleStroke consultation with a neurologist will be initiated. The remote neurologist will confirm eligibility, review imaging and labs, confirm consent, recommend the alteplase dose (0.9 mg/kg total, 10% bolus over 2 min, remainder over 1 hour), and guide post-dosing care. Patients will be monitored for BP, sensorium, deficits, and hemorrhage, with repeat CT at 24 hours or earlier if worsening. Patients with poor neurological status or complications may be transferred to a central hospital for expert care. Follow-up will extend to 3 months.

Endpoints of Interest:

Primary Outcomes:

Rate of utilization of IV alteplase thrombolysis for AIS at peripheral hospitals.

3-month clinical outcomes (Good=mRS 0-2; Poor=mRS 3-6) comparing control and rtPA groups.

Rates of intracranial or systemic hemorrhage.

Secondary Outcomes:

Discharge clinical outcomes (Good=mRS 0-2; Poor=mRS 3-6) comparing control and rtPA groups.

Time from patient arrival to initiation of TeleStroke Consult.

Door-to-Needle time for rtPA administration.

Rates of TeleStroke Consultations for acute stroke from peripheral hospitals.

Frequency of patient transfers to central hospitals.

Frequency of ICU admissions required.

Estimated cost of care: Comparison among Controls and rtPA Groups.

Statistical Analysis:

A stepped-wedge randomized model will guide implementation. Data from 30 patients managed conventionally will be documented at each center prior to thrombolysis initiation. After at least 20 thrombolysis encounters per peripheral hospital, overall outcomes will be analyzed. Continuous variables will be summarized using means/SDs or medians/quartiles, and categorical variables using frequencies/percentages. Analyses will be 2-tailed (p<0.05) using SPSS-21. Univariate methods will compare endpoints, and logistic regression will explore factors influencing outcomes. Cost-benefit analysis will compare TeleStroke-based management to conventional methods.

Significance to Oman and Benefits:

This initiative addresses a critical gap in acute ischemic stroke care by extending access to thrombolysis, currently largely inaccessible in many Omani peripheral communities. Successful implementation will align Omani stroke care with current international standards, potentially reducing stroke-related mortality and long-term morbidity. The expected reduction in long-term disability care costs is anticipated to offset program implementation and management expenses. This project will also foster ongoing skilled manpower development in acute care, telemedicine, and TeleStroke technology within Oman. While replicating studies conducted elsewhere, this research is vital to address local limitations such as telecommunications access, technological constraints, and community/hospital acceptability specific to Oman.

Tipo de estudo

Intervencional

Inscrição (Estimado)

200

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Arunodaya R Gujjar, MD, FRCP
  • Número de telefone: +968 95154022
  • E-mail: arunoday@squ.edu.om

Estude backup de contato

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Age >18 years. Acute neurologic deficits due to cerebral ischemia/infarction. Clearly defined onset with duration from stroke onset of <4.5 hours. Significant neurological deficit (usually NIHSS score of 4-25).

Exclusion Criteria:

  • CT brain shows showing evidence of intracranial hemorrhage
  • CT brain showing acute or subacute infarct of size about >1/3 Middle Cerebral Artery territory.
  • Arterial puncture at non compressible site in previous 7 days
  • History of previous intracranial hemorrhage.
  • Intracranial neoplasm, AV malformation, or aneurysm
  • Recent head injury OR intracranial or intraspinal surgery in last 3 mo.
  • Persistent Elevated BP >185/110 mm Hg despite treatment.
  • Active ongoing internal bleeding.
  • Platelet count <100 000/mm3.
  • Current use of NOACs OR warfarin with INR >1.7 OR Inj.Enoxaparin/Heparin in therapeutic dose
  • Blood glucose concentration <2.7mmol/L (<50mg/dl).

Relative contraindications: (may consider IV alteplase on individual evaluation).

  • Seizure at onset with post ictal residual neurological deficit.
  • Signs of mild stroke in isolation or rapidly improving symptoms.
  • Pregnancy.
  • Recent GI or UT hemorrhage within the last 21 days.
  • Recent MI within previous 3 months (to exclude anterolateral infarct / STEMI)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Thrombolysis arm
This arm includes patients with Acute ischemic stroke treated with thrombolysis using TeleStroke consultation
Thrombolysis using TeleStroke consultation with Neurologist
Outros nomes:
  • rt-PA, TNK
Sem intervenção: Control Arm
This arm includes age, gender matched patients with Acute Ischemic stroke who are not treated by thrombolysis.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
90 day outcome
Prazo: 90 days
Clinical outcome on modified Rankin Score at 90 days. This scale rates outcome from 0 to 6, with 0=no symptoms, 5=bed bound requiring assistance, 6=dead.
90 days
Discharge Outcome
Prazo: At discharge (assessed up to 5 days)
Clinical outcome on modified Rankin Score at discharge from hospital (assessed up to 5 days). This scale rates outcome from 0 to 6, with 0=no symptoms, 5=bed bound requiring assistance, 6=dead.
At discharge (assessed up to 5 days)
Rate of Thrombolysis
Prazo: At admission and initial management- 2 hours
Rate of utilization of IV alteplase / tenecteplase thrombolysis for acute ischemic stroke at peripheral hospitals
At admission and initial management- 2 hours

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Intracranial Hemorrhage Rate
Prazo: 24 hours
Rate of symptomatic intracranial hemorrhage at 24 hours of IV thrombolysis
24 hours
Door to Needle time
Prazo: 1 hour
Time from Triage arrival of patient to time IV thrombolysis is initiated
1 hour

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Investigador principal: Arunodaya R Gujjar, MD, DM, FRCP, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
  • Diretor de estudo: Sanjay Jaju, MD, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de agosto de 2026

Conclusão Primária (Estimado)

30 de dezembro de 2026

Conclusão do estudo (Estimado)

30 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

16 de julho de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de julho de 2026

Primeira postagem (Real)

22 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de julho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

After completion of study, anonymized IPD data can be shared on request by eligible researchers.

Prazo de Compartilhamento de IPD

Dec 2026 to Dec 2027

Critérios de acesso de compartilhamento IPD

After completion of study, anonymized IPD data can be shared on request by eligible researchers.

Tipo de informação de suporte de compartilhamento de IPD

  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever